In general, our findings suggested that CPNE1 might potentially act as a prognostic biomarker in ccRCC and highlighted the potential value of the CPNE1/EGFR/STAT3 axis as a promising target for combating ccRCC progression. The gene discussed is CPNE1; the disease is nonpapillary renal cell carcinoma.